News

In recent years, the new cancer cases and fatalities have been increasing sharply around the world, with China bearing the heaviest toll of this increase. The latest edition

The loan funds will be used to support Lymphoseek commercialization activities, advance the company’s clinical pipeline, accelerate certain development programs, repay certain of the company’s existing outstanding indebtedness

Debiopharm Research & Manufacturing boasts 35 years of expertise in drug development including chemical synthesis, formulation improvement and manufacturing. Major investments have been made since 2007 to automate

This action is being taken because of a pharmacist report that one bottle of Pfizer’s Effexor XR contained one capsule of Tikosyn (dofetilide) 0.25mg in addition to the

Sirturo is indicated when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. The approval follows a positive opinion from the Committee for

The preclinical Focal Adhesion Kinase (FAK) inhibitors originate from the Australian Cancer Therapeutics CRC (CTx). According to the companies the two licenses include fees, milestones and royalty payments.

About 500 patients will be enrolled in the trial, which will compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone. The company intends to

Under the deal, ProBioGen is granting Merus the non-exclusive right to use the GlymaxX technology to improve the ADCC (Antibody-Dependent Cell-Mediated Cytotoxicity) activity of one of its lead

Regulus Therapeutics’ Phase I study is being conducted in the Netherlands. Primary objective of the Phase I study is to assess the safety and tolerability of RG-101, while